Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 469, Issue -, Pages 38-47Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2017.05.036
Keywords
Thyroid cancer cells; Epigenetic writers; erasers and readers; Histone deacetylase and acetyl transferase; Epigenetic drugs
Categories
Funding
- Fondazione Umberto Di Mario
Ask authors/readers for more resources
Genomic and epigenetic alterations are now being exploited as molecular targets in cancer treatment. Abnormalities involving the post-translational modification of histones have been demonstrated in thyroid cancer, and they are regarded as promising molecular targets for novel drug treatment of tumors that are resistant to conventional therapies. After a brief overview of the histone modifications most commonly associated with human malignancies, we will review recently published preclinical and clinical findings regarding the use of histone-activity modulators in thyroid cancers. Particular attention will be focused on their use as re differentiating or anti-proliferating agents, the differential effects observed when they are used alone and in combination with other targeted drugs, and current prospects for their use in the treatment of thyroid cancer. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available